Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. - Wikidata - awgldk - TriplyDB

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.

http://www.wikidata.org/entity/Q44662293

about

Paroxetine versus other anti-depressive agents for depression Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics New targets for rapid antidepressant action.Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants.Efficacy comparison of duloxetine and SSRIs at doses approved in Japan.Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.Short-term duloxetine administration affects neural correlates of mood-congruent memory.Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression.Antidepressant prescribing patterns in Korea: results from the clinical research center for depression study Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.'In my life antidepressants have been…': a qualitative analysis of users' diverse experiences with antidepressants Suicidal ideation and the subjective aspects of depression Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level Prediction of response within the first 3 days to treatment with paroxetine for depression Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.Differential effects of chronic antidepressant treatment on shuttle box escape deficits induced by uncontrollable stress.Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?The importance of early symptom relief in antidepressant treatment: focus on agomelatine.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

P2860

Q24197507-2D122329-0F43-4E08-9A51-3F61A9CBDC8F Q24647799-21B52E3C-426F-4DD3-A168-1B0D9E2CB06A Q28300843-FE0DD262-E3B9-41F6-8CF1-C7DDC8C2C304 Q28736049-E0D58B8A-04A7-46AF-93CB-547C7F9CE053 Q31163645-764ECA9F-2846-42D6-9ED1-36F96F51C95D Q33724051-83C12F21-C64E-458F-A93B-E0F267F98D17 Q34444632-46E04311-6E82-498B-8C5B-045C15F39E30 Q34507177-54BCC5CA-4EF0-4100-AE60-F21AC2FE2317 Q34569403-8C32B9A9-630E-4A8C-A1CE-75FD27DE91A3 Q34590507-D79A8383-5A22-4E41-894B-7FB8E0BDE245 Q34640986-149046D8-67BF-4774-BBDF-B2532EDF891A Q34660724-639FBC93-D36E-47E8-8F28-9A694BA7701C Q34977592-3A6BEF8D-1F69-41B1-B7FD-4E920F3CEAFF Q35036911-354EDF04-F441-4016-9743-C8FBEFF4772D Q35153746-F6F4BA67-F6A3-4AED-B1B8-79246F90254D Q35222781-E6CDE8D1-FBE7-4525-A890-12529DFADDBD Q35223758-BFB8E5C8-FC39-4C36-95B6-2618642AF5B2 Q35238344-992A457B-C91A-4F0C-9597-09908653A22F Q35547495-733847F7-B70C-47F0-8CB6-95575B9153EE Q36013727-28409155-1701-4775-A908-3DEDA3B68B2C Q36031638-E91045F2-C661-46A9-94C4-B4E4F6F82B8C Q36223676-84E7BCEC-09EA-4FB5-B2C1-41ADAB64318F Q36538423-64E24983-0B30-4CC0-A2C0-03CB40E7754F Q36634249-03390432-7817-4F3E-8241-F53B53C2F874 Q36956511-0C7DABEE-2F90-47E9-9503-AB232B53F27C Q36972675-DD7D75A3-AEC5-4891-9901-79CE3E3E2B5E Q37147173-F977F494-4360-464A-A07D-591839CEB283 Q37307278-0E178CA1-B9BD-4E01-A476-396369A6A082 Q37307331-D153F3FB-8ABD-4930-AC81-20462E42F9BA Q37311889-9AB98D0A-1018-4CF2-9EC1-626A153CA1D1 Q37371545-DDE85D22-3503-44E9-907B-748EC6449CB8 Q37486653-82854586-D432-4A14-821B-1B21CC33F94A Q37668009-F3150354-9255-4C1C-A198-9305D8BDFF90 Q37709437-41E93F43-23A2-464E-AE67-4CF3F3053503 Q37735580-0643C5E7-3899-4516-AFDF-68B31AB8EA10 Q37776075-DA059BA2-501B-4416-89C5-979E37B42997 Q37891098-7AE9A51D-77B4-44CF-A863-4F10B32822D5 Q38066275-B03A2B3C-4C99-4DF8-BAA9-374E0C6CC0AA Q38123516-F759E5EE-0940-4CF9-A1EF-BCAC04816580 Q38476909-A65AD1BA-5589-4D6D-BF3B-C4F39AA986CF

P2860

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.

http://www.wikidata.org/entity/Q44662293

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Onset and early behavioral eff ...... nts and placebo in depression.

@en

Onset and early behavioral eff ...... nts and placebo in depression.

@nl

type

label

Onset and early behavioral eff ...... nts and placebo in depression.

@en

Onset and early behavioral eff ...... nts and placebo in depression.

@nl

prefLabel

Onset and early behavioral eff ...... nts and placebo in depression.

@en

Onset and early behavioral eff ...... nts and placebo in depression.

@nl

P1433

Q44662293-59A248CC-F8E4-46B9-8BD0-7867A2539EB8

P1476

Q44662293-D9447AB5-17C4-4EA8-9A7B-F53CB7603896

P2093

Q44662293-2F776650-2DCA-49D2-A273-7D5BF753DF9E

Q44662293-3BBD9EC8-97FF-4D58-9A55-74307BF10FDB

Q44662293-7E345E34-261B-4A74-BAF6-7338612BAA33

Q44662293-A2EDECF5-D558-4997-9C94-7916F60F9A9A

Q44662293-E08A4933-900F-4272-A441-7E602E4AD0F2

Q44662293-E5883EF0-4D26-456C-A69E-CEE5B47F460B

Q44662293-FFEA3149-DF9C-4AF2-AD9C-28CACA483851

P2860

Q44662293-00978925-5168-4F98-AB12-BF710DDE22C4

Q44662293-054AA813-5884-48EA-A0C3-9145E116A17D

Q44662293-10859CBC-C831-44A1-983D-8D9F1EF32505

Q44662293-1495DF51-922C-42F8-85B4-BBAD8B6B1918

Q44662293-257FA8ED-2C15-40CA-817C-3FDA988D56AE

Q44662293-38985FF5-6A86-4B8C-AA31-AE92987BEBAA

Q44662293-48B54206-4A38-4B31-9DB3-3F6719F5FAAE

Q44662293-4E29CB20-3EB4-4EEC-9D86-6A7AA8B5AD60

Q44662293-4EECFEEA-10C4-47DA-8555-B95F29BD8836

Q44662293-533855BE-AD0C-4405-8E7B-5EAC8336126D

P2888

Q44662293-CA584A83-DEA9-429F-B87D-8BF2A642245B

P304

Q44662293-94347E58-8B3D-48FC-A5C6-0B4015825CFB

P31

Q44662293-80A66B58-969F-4EFE-8C0C-D4B32FDCA158

P356

Q44662293-5B360403-2CF6-496B-B50F-81C131D37C41

P407

Q44662293-2916CA4B-F08E-48DA-9733-22DAFAB77510

P433

Q44662293-E4AFBC34-303C-4159-885F-4E77512FF3E5

P478

Q44662293-156F3FE7-D695-4E49-8B32-06419F06A7FC

P577

Q44662293-ACB24441-A65A-4AA9-9D7B-8ED2A565C836

P5875

Q44662293-5C0FE8ED-1857-4315-B0F4-FF8921D3BC80

P6179

Q44662293-DF08385F-56CA-4196-B5D4-D383FB1CBA77

P698

Q44662293-C70D16C1-CC4B-4212-B44B-D38292D06766

P921

Q44662293-26E93164-AD34-4719-A2C0-F30737990CCC

Q44662293-CB780CA9-ADDF-4756-9CE1-D02B0024A8B9

P356

P1433

Neuropsychopharmacology

P1476

Onset and early behavioral eff ...... nts and placebo in depression.

@en

P2093

Alan Frazer

http://www.w3.org/2001/XMLSchema#string

Charles L Bowden

http://www.w3.org/2001/XMLSchema#string

Janet L Tekell

http://www.w3.org/2001/XMLSchema#string

John P Houston

http://www.w3.org/2001/XMLSchema#string

Martin M Katz

http://www.w3.org/2001/XMLSchema#string

Nancy Berman

http://www.w3.org/2001/XMLSchema#string

Steve Brannan

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Random-effects models for longitudinal data

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

Serotonin and stress.

Therapeutic advances: paroxetine for the treatment of social anxiety disorder.

Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation.

The treatment of depressive states with G 22355 (imipramine hydrochloride).

A diagnostic interview: the schedule for affective disorders and schizophrenia.

Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine.

Modulatory role of serotonin in neural information processing: implications for human psychopathology.

P2888

P304

566-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300341

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8999606

http://www.w3.org/2001/XMLSchema#string

P6179

1047826003

http://www.w3.org/2001/XMLSchema#string

P698

14627997

http://www.w3.org/2001/XMLSchema#string

P921